SNY (SNY) Stock Price & Analysis
SNY (SNY) rose 1.94% to USD 44.73 as of June 9, 2026 at 23:55 UTC, according to Nexqual real-time market data.
SNY last closed at USD 43.88; the session ranged USD 44.33–44.82 on volume of 2,739,241 shares. Market capitalization is $107.07B, with a 52-week range of USD 42.28–52.68 (NMS). Source: Nexqual, June 9, 2026 at 23:55 UTC.
Key Statistics (as of June 9, 2026 at 23:55 UTC)
| Price | USD 44.73 |
|---|---|
| Change | ▲ 1.94% (up) |
| Previous Close | USD 43.88 |
| Open | USD 44.45 |
| Day Range | USD 44.33 – 44.82 |
| 52-Week Range | USD 42.28 – 52.68 |
| Volume | 2,739,241 shares |
| Market Cap | $107.07B |
| Exchange | NMS |
Technical Analysis (SNY)
Nexqual's technical model rates SNY "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.11 (neutral) |
| vs SMA50 | Below (USD 45.3) |
| MACD | -0.2 (negative) |
Analyst Ratings (SNY)
Wall Street analysts rate SNY "Buy" based on 9 analysts, with a mean price target of USD 55.9 (range USD 51–63), per Nexqual as of June 9, 2026 at 23:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 55.9 |
| High Target | USD 63 |
| Low Target | USD 51 |
| Buy / Hold / Sell | 5 / 5 / 0 |
Earnings (SNY)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.13 |
| Revenue Estimate | $11.00B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.1 vs est 1.03 ▲ beat |
| 2025-12-31 | USD 0.91 vs est 0.85 ▲ beat |
| 2025-09-30 | USD 1.69 vs est 1.57 ▲ beat |
| 2025-06-30 | USD 0.91 vs est 1 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financials & Fundamentals (SNY)
| Total Revenue | $47.35B |
|---|---|
| Revenue Growth (YoY) | +6.00% |
| Gross Margin | +72.36% |
| Operating Margin | +20.00% |
| Profit Margin | +15.95% |
| ROE | +6.58% |
| Debt / Equity | 27.37 |
| Current Ratio | 1.01 |
| Total Cash | $5.54B |
| Total Debt | $20.02B |
| Free Cash Flow | $16.67B |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financial Health Score (SNY)
Nexqual rates SNY's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:55 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 20% |
| Balance Sheet | Strong — $5.54B cash vs $20.0B debt |
| Cash Flow | Strong — FCF $16.7B, 38% margin |
| Efficiency | Mixed — ROE 7%, ROA 4.7% |
Ownership (SNY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +8.90% |
| Shares Outstanding | 2.39B |
| Float | 2.17B |
| Short % of Float | +0.31% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Leadership (SNY)
SNY is led by Belen Garijo Lopez (age 65), CEO & Director, per Nexqual as of June 9, 2026 at 23:55 UTC.
| CEO & Director | Belen Garijo Lopez (age 65) |
|---|---|
| Executive VP & CFO | François-Xavier Roger (age 63) |
| Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | Pierre Chancel (age 68) |
| Executive Vice President of General Medicines | Olivier Charmeil (age 62) |
Major Backers & Investors (SNY)
Notable institutional backers of SNY include Dodge & Cox Inc., Morgan Stanley, Fisher Asset Management, LLC, according to Nexqual as of June 9, 2026 at 23:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 19.78% |
| Morgan Stanley | 4.69% |
| Fisher Asset Management, LLC | 4.29% |
| Bank of America Corporation | 3.56% |
| Franklin Resources, Inc. | 2.69% |
| Invesco | 2.48% |
| Barrow, Hanley Mewhinney & Strauss, LLC | 2.21% |
| JPMorgan | 2.1% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GSK | GSK plc | USD 51.25 | ▼ 0.52% |
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
| AZN | AstraZeneca PLC | USD 183.43 | ▼ 1.36% |
| RHHBY | Roche Holding Ltd | USD 50.01 | ▼ 2.86% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 616.18 | ▼ 3.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:55 UTC. This page is informational and not investment advice.